• 1
    Moreau R, Lebrec D. Molecular and structural basis of portal hypertension. Clin Liver Dis 2006; 10: 445-457.
  • 2
    Kim MY, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol 2010; 16: 347-352.
  • 3
    Iwakiri Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int 2012; 32: 199-213.
  • 4
    Zipprich A. Hemodynamics in the isolated cirrhotic liver. J Clin Gastroenterol 2007; 41( Suppl 3): S254-258.
  • 5
    Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. HEPATOLOGY 2002; 35: 478-491.
  • 6
    Rodriguez-Vilarrupla A, Lavina B, Garcia-Caldero H, Russo L, Rosado E, Roglans N, et al. PPARalpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. J Hepatol 2010; 56: 1033-1039.
  • 7
    Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137: 354-366.
  • 8
    Kaur J, Reddy K, Balakumar P. The novel role of fenofibrate in preventing nicotine- and sodium arsenite-induced vascular endothelial dysfunction in the rat. Cardiovasc Toxicol 2010; 10: 227-238.
  • 9
    Clockaerts S, Bastiaansen-Jenniskens YM, Feijt C, Verhaar JA, Somville J, De Clerck LS, et al. Peroxisome proliferator activated receptor alpha activation decreases inflammatory and destructive responses in osteoarthritic cartilage. Osteoarthritis Cartilage 2011; 19: 895-902.
  • 10
    Gelosa P, Banfi C, Gianella A, Brioschi M, Pignieri A, Nobili E, et al. Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats. J Pharmacol Exp Ther 2010; 335: 324-331.
  • 11
    Zhang F, Lu Y, Zheng S. Peroxisome proliferator-activated receptor-gamma cross-regulation of signaling events implicated in liver fibrogenesis. Cell Signal 2012; 24: 596-605.
  • 12
    Friedman SL. A silent partner no longer — sinusoidal endothelial cells in liver homeostasis and disease. J Hepatol 2012; 56: 1001-1002.
  • 13
    Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000; 275: 35715-35722.
  • 14
    Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. HEPATOLOGY 2004; 39: 1286-1296.
  • 15
    Takashimizu S, Kojima S, Nishizaki Y, Kagawa T, Shiraishi K, Mine T, et al. Effect of endothelin A receptor antagonist on hepatic hemodynamics in cirrhotic rats. Implications for endothelin-1 in portal hypertension. Tokai J Exp Clin Med 2011; 36: 37-43.
  • 16
    Lavina B, Gracia-Sancho J, Rodriguez-Vilarrupla A, Chu Y, Heistad DD, Bosch J, et al. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. Gut 2009; 58: 118-125.
  • 17
    Van Landeghem L, Laleman W, Vander Elst I, Zeegers M, van Pelt J, Cassiman D, et al. Carbon monoxide produced by intrasinusoidally located haem-oxygenase-1 regulates the vascular tone in cirrhotic rat liver. Liver Int 2009; 29: 650-660.
  • 18
    Serste T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. HEPATOLOGY 2010; 52: 1017-1022.